NCT06462781View on ClinicalTrials.gov

Localized Injection of Lidocaine and Glucocorticoid for Headache Treatment Phase 1

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 15, 2024

Primary Completion Date

May 13, 2025

Study Completion Date

June 1, 2025

Conditions
Refractory Migraine
Interventions
DRUG

Lidocaine hydrochloride

Intra-arterial injection of 40mg lidocaine per middle meningeal artery (total 2 arteries) administered one time

DRUG

Methylprednisolone sodium succinate

Intra-arterial injection of 20mg methylprednisolone per middle meningeal artery (total 2 arteries) administered one time

Trial Locations (1)

08103

Cooper University Health Care, Camden

All Listed Sponsors
collaborator

Society of Vascular and Interventional Neurology

UNKNOWN

lead

The Cooper Health System

OTHER

NCT06462781 - Localized Injection of Lidocaine and Glucocorticoid for Headache Treatment Phase 1 | Biotech Hunter | Biotech Hunter